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Abstract
Objectives. To evaluate the association between improvements in physical function, fatigue and pain and
improvements in productivity at work and at home in patients treated with certolizumab pegol (CZP) in
combination with MTX.
Methods. Physical function, fatigue and pain were assessed in two CZP clinical trials (Rheumatoid
Arthritis PreventIon of structural Damage 1 and 2) using the HAQ-Disability Index (HAQ-DI), Fatigue
Assessment Scale (FAS) and Patient Assessment of Pain, with minimal clinically important differences
(MCIDs) defined as 50.22, 51 and 510 points, respectively. Work and home productivity were evaluated
using the RA-specific Work Productivity Survey (WPS-RA). The odds of achieving an HAQ-DI, FAS or pain
‘response’ at Week 12, defined as improvements 5MCID, were compared between CZP and control
groups. Improvements in productivity at Week 12 were compared between CZP-treated HAQ-DI, FAS
or pain responders and non-responders.
Results. The odds of achieving improvements 5MCID were five times higher for pain, and two to three
times higher for physical function and fatigue, in patients receiving CZP vs control. Per month, responders
reported significantly greater improvements in productivity at work and reduced interference of RA with
their work productivity than non-responders. Responders also reported significantly greater improvements
in productivity at home and participation in family, social and leisure activities.
Conclusions. This study demonstrated a clear association between patient-reported improvements in
physical function, fatigue and pain, and improvements in productivity both at work and home.
Key words: Rheumatoid arthritis, Certolizumab pegol, Physical function, Fatigue, Pain, TNF, Work productivity,
Household productivity, Daily activities.
Introduction
As a consequence of their disease, patients with RA
experience pain, fatigue and disability that can
significantly impact their everyday lives. Patients have
identified pain, associated with the inflammation and
joint destruction that characterize the disease, as one
of the most important outcomes for RA treatment and
one of the main reasons for which they seek medical
care [1, 2]. Fatigue, another common symptom of the
disease, has been described by patients as overwhelm-
ing and more intense compared with the typical tired-
ness experienced before being diagnosed with RA [1, 3].
The cause of fatigue is multi-factorial and involves the
inflammatory process, pain, anaemia, depression
and poor sleep quality [4, 5], with pain and sleep dis-
turbance demonstrating the strongest influence on fa-
tigue [4, 5].
1Erasmus MC – University Medical Center Rotterdam, Rotterdam, The
Netherlands,
2Kennedy Institute of Rheumatology Division, Imperial
College, London, UK,
3Division of Immunology and Rheumatology,
Stanford University School of Medicine, Palo Alto, CA, USA,
4Global Health Outcomes Research, UCB Pharma, Braine l’Alleud,
Belgium and
5Swedish Medical Center, University of Washington,
Seattle, WA, USA.
Correspondence to: Johanna M. Hazes, Erasmus MC – University
Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam,
The Netherlands. E-mail: j.hazes@erasmusmc.nl
Submitted 17 June 2009; revised version accepted 10 March 2010.
! The Author(s) 2010. Published by Oxford University Press on behalf of The British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
RHEUMATOLOGY
Rheumatology 2010;49:1900–1910
doi:10.1093/rheumatology/keq109
Advance Access publication 14 June 2010
C
L
I
N
I
C
A
L
S
C
I
E
N
C
ESymptoms of both pain and fatigue are associated with
impairments in physical function [5–7], which significantly
impact patients’ lives as well as society. Limitations in
physical function have been shown to affect patients’ abil-
ity to attend work and to perform paid and unpaid work
(e.g. employment and volunteer work) [8–10] and house-
hold activities, and to impair their ability to engage in
family, social and leisure activities [11–13]. These limita-
tions often force patients to seek additional support to
meet individual role obligations, including assistance
from family members or hired household personnel and
flexibility and job modifications from employers.
Since the majority of RA patients become work disabled
(i.e. unable to participate in paid work) within 10 years of
disease onset [14–16], research has focused on determin-
ing the predictors of work disability, including functional
status and RA signs and symptoms, which can be mod-
ified to improve work-related outcomes [16–21]. In add-
ition, research has focused on evaluating the impact of the
disease and its treatment on paid work in terms of prod-
uctivity, including the number of days absent from work
(absenteeism) as well as the number of days present at
work with reduced efficiency (presenteeism) [9, 22–25].
Few studies have evaluated the impact of RA on house-
hold work [11–13, 26], despite the fact that women do the
majority of household activities and that the incidence of
RA in women is three times that in men. Evaluations of
household activity limitations are particularly relevant in
established RA, where the majority of sufferers have left
the work force but still may be expected to participate in
their work roles at home, including cooking, cleaning and
child care. In addition, there are few studies on improve-
ment in paid and household work productivity and
improvement in the participation in family and social activ-
ities following symptom relief with newly available thera-
pies, such as anti-TNF agents, in established RA.
Certolizumab pegol (CZP) is the only PEGylated anti-
TNF agent approved for the treatment of RA. In patients
with active RA, CZP has been shown to rapidly improve
signs and symptoms and physical function, to relieve pain
and fatigue and to significantly improve productivity within
and outside the home as add-on therapy to MTX [27–31].
The objective of the present analysis was to evaluate the
association between clinically meaningful improvements
in physical function, fatigue and pain and improvements
in productivity at work and at home, as well as participa-
tion in family, social and leisure activities in patients with
active RA.
Patients and methods
Study design
This analysis used data from two multinational, Phase III,
multi-centre, double-blind, placebo-controlled studies
comparing the efficacy and safety of two dose regimens
of CZP added to MTX in patients with active RA who had
incomplete responses to MTX [27, 28]. The Institutional
Review Boards and Institutional Ethics Committees at
each study centre in both multinational trials approved
the studies, the subject information sheets and the in-
formed consent forms. The studies were carried out in
accordance with the International Conference on
Harmonization (ICH) E6 Note for Guidance on Good
Clinical Practice [ICH/Committee for Proprietary
Medicinal Products (CPMP) 135/95], the principles that
have their origin in the Declaration of Helsinki, and local
laws and regulations. All subjects (or their legally accept-
able representative) provided written informed consent
before taking part in the studies.
In Rheumatoid Arthritis Prevention of Structural Damage
(RAPID) 1 and 2, 982 and 619 patients were randomly
assigned to treatment, respectively. In each clinical trial,
patients were randomly assigned (2:2:1) to receive s.c.
CZP 200 or 400mg (preceded by three dosages of 400mg
at Weeks 0, 2 and 4) plus MTX, or placebo plus MTX,
every 2 weeks for 52 weeks (RAPID 1) or 24 weeks
(RAPID 2). Following screening, eligible patients were
assessed for efficacy at baseline; Weeks 1, 2, 4, 6, 8
(10, RAPID 1 only), 12, 14 and 16; and every 4 weeks
thereafter until Week 52 or 24 (or at withdrawal) for
RAPID 1 and RAPID 2, respectively. Patients who were
ACR20 non-responders at Week 12 (confirmed at Week
14) were to be withdrawn from study at Week 16 as per
the protocol. Patients who withdrew at Week 16 or who
successfully completed the trial were offered enrolment
in an open-label extension study of CZP 400mg every
2 weeks plus MTX.
The present analysis assesses the association between
clinically meaningful improvements in physical function,
fatigue and pain from baseline to Week 12 and improve-
ments in productivity at work and home in these two trials.
Data from the two CZP treatment groups (CZP 200mg
plus MTX and CZP 400mg plus MTX) from both trials
were pooled for analysis. Clinically meaningful improve-
ments were defined as changes from baseline greater
than or equal to the minimal clinically important difference
(MCID) for each outcome measure (physical function, fa-
tigue and pain). Patients reporting a clinically meaningful
improvement were considered responders. MCIDs were
used in this analysis as they are clinically relevant for pa-
tients and have been well studied and documented in the
literature. Week 12 was chosen as the assessment time
point for this analysis because treatment guidelines sug-
gest switching therapy if a response is not observed within
12 weeks [32].
Health outcome measures
Physical function
Physical function was assessed using the 20-item
HAQ-Disability Index (HAQ-DI), which evaluates the
degree of difficulty experienced by the patient in eight
categories of daily living: dressing and grooming, hygiene,
arising, eating, walking, reaching, gripping and outdoor
activities. Scores for each domain range from 0 (no diffi-
culty in performing the activity) to 3 (unable to do the ac-
tivity), with total index scores ranging from 0 to 3 [33].
Patients reporting a decrease of 50.22 points in the
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Outcomes associated with productivity in RAHAQ-DI, which is defined as the MCID [34, 35] from base-
line to Week 12, were considered responders.
Physical function was also assessed using the physical
functioning (PF) domain and physical component sum-
mary (PCS) scores of the Short Form 36-Item Health
Survey (SF-36) [36]. Patients reporting improvements
5MCID for the SF-36 PCS and PF scores (2.5 and
5 points, respectively) from baseline to Week 12 were
considered responders.
Fatigue
Fatigue (tiredness) was assessed by the Fatigue
Assessment Scale (FAS) [37, 38]. In this single-item, nu-
meric rating scale, patients are asked, ‘Please rate your
fatigue (weariness, tiredness) during the past week on a
scale of 0–10, where 0 is ‘‘no fatigue’’ﬄ and 10 is ‘‘fatigue’’
as bad as you can imagine’. Patients reporting a 51-point
decrease in the FAS (which is defined as the MCID based
on an internal anchor-based approach) [39] from baseline
to Week 12 were considered responders. In addition, fa-
tigue was assessed using the SF-36 vitality (VT) domain
[36]; those achieving at least a 5-point increase from
baseline to endpoint in VT scores were considered
responders [40].
Pain
Patients reported their level of arthritis pain using the
Patient’s Assessment of Pain Visual Analogue Scale
(VAS), a component of the ACR response criteria in RA
[41], by answering the query, ‘My pain at the time is...’b y
using a 100-mm VAS, where 0 is ‘no pain’ and 100 is
‘most severe pain’. It is well accepted that MCID for
100-mm VAS scales is an improvement of 10mm [42];
therefore, patients reporting 510-point decrease in pain
from baseline to Week 12 were considered responders.
Pain was also assessed using the SF-36 bodily pain (BP)
domain [36]; patients reporting a 55-point decrease from
baseline to Week 12 were considered responders [34, 36].
Productivity within and outside the home and daily
activities
The RA-specific Work Productivity Survey (WPS-RA) is
a novel, validated questionnaire developed to assess the
impact of RA on productivity at paid work outside the
home and work within the home and on family, social
and leisure activities over the preceding month [43].
During the recent OMERACT 9 meeting, based on avail-
able evidence supporting their validity, the WPS-RA was
one of the five selected instruments for assessing prod-
uctivity changes in RA [44]. The WPS-RA is based on
self-report and is interviewer administered, with a recall
period of 1 month. The survey, shown to be valid and
responsive to clinical changes [43], consists of nine ques-
tions. The first question addresses employment status
and provides additional information on job type for em-
ployed subjects and the status of those not employed. For
employed patients only, three questions assess absentee-
ism (full days of work missed due to arthritis) and present-
eeism (days with work productivity reduced by 550% due
to arthritis; does not include days counted in the previous
question) in the workplace, and rate of interference of RA
with work productivity on a scale of 0–10 (0: no interfer-
ence; 10: complete interference). The last five questions of
the survey, which are answered by all patients, are related
to productivity limitations at home and participation in
family, social and leisure activities over the previous
month as follows: number of days of household work
missed due to arthritis; days with household productivity
reduced by 550% (does not include days counted in the
previous question); days with outside help hired; rate of
interference with household productivity by RA on a scale
of 0–10; and days with family, social or leisure activities
missed.
The WPS-RA survey was assessed in the RAPID 1 and
2 trials at baseline (Week 0) and every 4 weeks until the
end of the study or until study withdrawal. Days missed
from work or activities due to scheduled per-protocol
study visits were not counted in the assessment.
Statistical methods
Analyses of response rates at Week 12 for physical func-
tion, fatigue and pain were conducted on the intent-
to-treat (ITT) populations for the RAPID 1 and 2 trials,
which were defined as all patients being randomly
assigned to receive treatment. Responder status was
determined based on the above definitions of MCID for
each measure (physical function, fatigue and pain) by
categorizing patients as responders if they achieved
improvement from baseline to Week 12 5MCID or non-
responders if they did not. Logistic regression models
(with treatment as factor and baseline HAQ-DI, fatigue
or pain scores as covariates) were conducted to evaluate
the odds of being a responder by physical function, fa-
tigue and/or pain at Week 12. Additional analyses were
also performed using other MCID thresholds and using a
responder definition based on 20% improvement in
HAQ-DI scores from baseline.
Analyses of the relationship between improvements in
each health outcome measure and changes in productiv-
ity were conducted on observed data at Week 12 [i.e. only
on patients with non-missing data at Week 12 in both
productivity and outcome measures (physical function, fa-
tigue or pain)] from the pooled CZP dose groups (200 and
400mg) from the two RAPID studies. Analyses of prod-
uctivity at home and daily activities were included in all
patients (employed plus unemployed) at Week 12, while
analyses of productivity outside home were conducted in
the employed population only. The relationship between
improvements in each health outcome and changes in
productivity was examined by comparing differences in
WPS-RA changes from baseline to Week 12 in responders
vs non-responders by physical function (HAQ-DI, SF-36
PCS and PF), fatigue (FAS and SF-36 VT) and pain (pain
VAS and SF-36 BP). The tests of comparison were con-
ducted using a non-parametric bootstrap t-method [45].
As the WPS-RA questions capture lost days or rate
of interference, improvement in productivity within and
outside the home and daily activities is attained when
there is a decrease in the WPS response, which
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change indicates a loss or worsening. In other words,
the higher the negative mean change (in absolute value),
the better the impact of the therapy on productivity and
daily activities.
Results
Population characteristics at baseline
A total of 1601 patients were enrolled in the RAPID studies
(982 patients in RAPID 1 and 619 in RAPID 2). Baseline
demographics, disease characteristics and health out-
comes measures were similar across both trials
(Tables 1 and 2). On average, patients were 52 years of
age, had experienced RA for 6 years and reported mod-
erate to severe impairment in physical function, fatigue
and pain (Tables 1 and 2). More than three quarters of
patients were female (Table 1).
Full details regarding the baseline employment status of
patients in these trials have been previously published
[29]. In brief, 40% of patients were employed outside
the home at baseline (Table 1). These patients reported
missing an average of 3–4 full days of paid work and had
an additional 7–9 days on average of work with product-
ivity reduced by at least 50% in the previous month due to
RA (Table 2). RA also had substantial impact on house-
hold work productivity and participation in family, social
and leisure activities (regardless of employment status;
Table 2). On average, patients missed 7–8 full days of
household work and had an additional 10–11 days of
household work with productivity reduced by at least
50% due to RA during the previous month. They also re-
ported missing on average 5–6 days of family, social and
leisure activities during the previous month.
Impact of treatment
Treatment with CZP 200 or 400mg plus MTX significantly
improved physical function and productivity and reduced
pain and fatigue in patients with active RA [27–29].
Response rates based on the MCIDs for physical function,
fatigue and pain were higher in patients receiving CZP
plus MTX (68–76%) compared with patients receiving pla-
cebo plus MTX (41–52%) [odds ratio (OR) 2.9–5.5 for CZP
plus MTX vs placebo plus MTX; P40.01], and were similar
for the two CZP dose groups (Table 3).
Associations between productivity within and outside
the home and physical function, fatigue and pain in
CZP-treated patients
Productivity outside the home
Physical function. Although HAQ-DI responders and
non-responders reported similar reductions in absentee-
ism by Week 12 (mean decreases of 2.1 vs 1.8 days,
respectively; P=0.622; Fig. 1a), responders reported
significantly higher decreases in presenteeism (mean
changes of 6.4 vs 1.9 days, respectively; Fig. 1b) and
in the rate of RA interference with their work productivity
(mean decrease of 2.5 vs 1.4 points on a scale of 0–10;
Fig. 1c) compared with non-responders. Comparable as-
sociations between work productivity and physical func-
tion as reported by SF-36 PF domain scores were evident
for all three measures of work productivity (Table 4);
associations were also evident between SF-36 PCS and
PF domain scores and the rate of interference of RA with
work productivity (Table 4).
Fatigue. FAS responders reported significantly higher
decreases in presenteeism by Week 12 (mean changes
of 6.0 vs 2.7 days, respectively; Fig. 1b) and signifi-
cantly higher reductions in the rate of RA interference
with their productivity at work (average decrease of
2.5 vs 1.3 on a 0–10 scale; Fig. 1c) compared with
non-responders. No significant differences were reported
between responders and non-responders for reductions
in absenteeism (Fig. 1a). Similar associations between
work productivity and fatigue, as evaluated by the SF-36
VT domain, were evident for all three measures of work
productivity (Table 4).
Pain. Although responders and non-responders by pain
VAS reported similar reductions in absenteeism at paid
TABLE 1 Baseline demographical characteristics in RAPID trials (ITT population)
Characteristics RAPID 1 (N=982) RAPID 2 (N=619)
Age, mean (S.D.), years 52.0 (11.6) 51.9 (11.5)
Gender, female, % 83.2 81.6
Disease duration, mean (S.D.), years 6.1 (4.3) 6.2 (4.2)
Number of previous DMARDS, mean (S.D.) 1.3 (1.3) 1.2 (1.3)
DAS-28 (ESR), mean (S.D.) 6.9 (0.8) 6.8 (0.8)
RF (514IU/ml), n (%) 802 (81.8) 462 (76.9)
Employment status
a, n (%)
Employed 370 (37.7) 245 (39.6)
Homemakers 128 (13.0) 45 (7.3)
Retired 178 (18.1) 173 (27.9)
Unable to work due to RA 188 (19.1) 148 (23.9)
Other (not employed) 25 (2.5) 5 (0.8)
aAs captured by the WPS-RA; percentages are computed on the overall ITT population. DAS-28(ESR): Disease Activity Score
based on 28-joint count ESR.
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Outcomes associated with productivity in RAwork at Week 12 (mean changes of 2.2 vs 1.6 days,
respectively; Fig. 1a), responders reported significantly
higher reductions in presenteeism at work (average
change of 6.0 vs 2.1 days, respectively; Fig. 1b) and
had significantly higher reductions in RA interference with
productivity at work (mean decrease of 2.6 vs 0.7 points
on a scale of 0–10; Fig. 1c). Similar associations between
work productivity and pain, when evaluated by the SF-36
BP domain, were evident for all three measures of work
productivity (Table 4).
Productivity at home and daily activities
Physical function. HAQ-DI responders reported signifi-
cantly higher decreases in the number of household
work days missed by Week 12 (mean decreases of 5.1
vs 2.4 days, respectively; Fig. 2a) and in the number of
days with productivity in the home reduced by 550%
(mean change of 6.1 vs 3.4 days, respectively;
Fig. 2b) compared with non-responders. Responders
also reported significantly higher reductions than
non-responders in days of missed family, social and leis-
ure activities (mean changes of 3.9 vs 2.5 days, re-
spectively; Fig. 2c); in days with hired outside help per
month (mean changes of 3.0 vs 1.9 days, respectively;
Fig. 2d) and the interference of RA with their household
work productivity (mean decreases of 2.6 vs 1.0 points on
a scale of 0–10; Fig. 2e). Similar trends in improvements
were evident when response was defined based on SF-36
PCS and PF domain scores (Table 4).
TABLE 2 Baseline physical function, fatigue, pain and productivity in RAPID trials (ITT population)
Characteristics RAPID 1 (N=982) RAPID 2 (N=619)
HAQ-DI (0–3.0)
a, mean (S.D.) 1.7 (0.6) 1.6 (0.6)
FAS (0–10)
b, mean (S.D.) 6.5 (2.0) 6.5 (1.9)
Pain VAS (0–100)
c, mean (S.D.) 63.1 (18.9) 60.9 (20.2)
SF-36
PCS summary score (0–50), mean (S.D.) 30.8 (6.5) 30.9 (6.2)
Physical function domain score (0–100), mean (S.D.) 32.9 (21.1) 32.3 (20.3)
VT domain score (0–100), mean (S.D.) 35.3 (18.2) 37.0 (17.7)
BP domain score (0–100), mean (S.D.) 29.5 (15.4) 30.2 (15.0)
WPS-RA, mean (S.D.)
Days of paid work missed due to RA per month
d 3.9 (8.0) 3.3 (6.8)
Days with productivity at work reduced by 550% due to RA per month
e 7.1 (8.5) 8.8 (8.6)
Rate of RA interference on work productivity per month
f 5.2 (2.6) 5.5 (2.3)
Days of household work missed due to RA per month
d 8.1 (8.5) 6.9 (7.4)
Days with household productivity reduced by 550% due to RA per month
e 10.4 (8.4) 10.8 (8.2)
Days of missed family, social or leisure activities due to RA per month
d 6.1 (8.7) 5.0 (7.5)
Days with outside hired help per month
d 5.4 (9.0) 5.0 (8.7)
Rate of RA interference on household work productivity per month
f 6.2 (2.3) 5.9 (2.2)
aHAQ-DI scores range from 0 to 3, with lower scores indicating improvements in physical function.
bFAS scores range from
0 to 10, with lower scores indicating less fatigue.
cScores for patient’s assessment of arthritis pain range from 0 to 100mm,
with lower scores indicating relief in arthritis pain.
dRange is 0–30 (in past month).
eRange is 0–30 (in past month) and does not
include days counted in previous question.
fRange is 0–10, where 0 indicates no interference and 10 indicates complete
interference.
TABLE 3 Response rates at Week 12 in physical function, fatigue and pain in the pooled RAPID trials (ITT population)
Response
PBO+MTX
(n=326)
CZP 200mg+MTX
(n=639)
CZP 400mg+MTX
(n=636)
HAQ response
a
n (%) 125 (43.7) 395 (68.1) 416 (71.2)
OR vs PBO
b 2.93* 3.41*
FAS response
a
n (%) 148 (51.8) 439 (75.7) 435 (74.5)
OR vs PBO
b 3.54* 3.35*
Pain VAS response
a
n (%) 117 (40.9) 430 (74.0) 445 (76.1)
OR vs PBO
b 5.08* 5.54*
aResponse is defined as an improvement from baseline to Week 12 5MCID (in absolute value); MCID equals 0.22 (HAQ-DI);
10 (pain VAS); 1 (FAS). Response rates are computed on available data at Week 12;
bOR and P-value from logistic regression
with treatment as factor and baseline HAQ-DI, pain VAS or FAS score as covariates, respectively; *P40.001. PBO: placebo.
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cantly higher reductions than non-responders in the
number of days missed of household work due to RA
(mean changes of 4.9 vs 2.5 mean days, respectively;
Fig. 2a); in days of household work with productivity
reduced by 550% (mean changes of 6.2 vs 2.7
days, respectively; Fig. 2b); and in days of missed
family, social and leisure activities (mean changes of
4.1 vs 1.8 days; Fig. 2c). Responders also reported
significantly higher reductions in days with hired outside
help per month (mean changes of 3.1 vs 1.5 days;
Fig. 2d) and in the interference of RA with household
productivity (2.5 vs 0.9 average decrease on a scale of
0–10; Fig. 2e) than non-responders. Similar results for re-
sponders defined based on improvements in the SF-36 VT
domain were also evident (Table 4).
Pain. Responders by pain VAS had significantly higher
decreases in days missed of household work by Week 12
(mean changes of 5.1 vs 2.1 days, respectively;
Fig. 2a); in days with household productivity reduced by
50% (mean changes of 6.1 vs 3.1 days; Fig. 2b); in
days lost of family, social and leisure activities (4.0 vs
2.1; Fig. 2c); in days with hired outside help per month
(3.1 vs 1.5; Fig. 2d); and RA interference with house-
hold work (2.6 vs 0.7 average decrease on a scale of 0–10;
Fig. 2e) compared with non-responders. Similar findings
were evident in responders defined by improvements in
the SF-36 BP domain (Table 4).
Sensitivity analysis
A sensitivity analysis was conducted to determine the
impact of different thresholds to define clinically meaning-
ful improvements in physical function, fatigue and pain on
reported outcomes for work outside and within the home
as well as participation in family, social and leisure activ-
ities. For each WPS-RA question, responder status was
determined for three levels of clinical improvement:
HAQ-DI (MCID and sensitivity thresholds assessed=0.22,
0.50 or 0.70), FAS (1, 2 or 3) and pain VAS (10, 20 or 30). In
general, associations between productivity and physical
FIG.1Mean changes in paid work productivity from baseline to Week 12 by responder status (observed data, employed
ITT population, pooled RAPID 1 and 2 CZP 200mg+400mg groups). Response is defined as change from baseline to
Week 12 5MCID (in absolute value), non-response is defined as mean change from baseline to Week 12 <MCID. Recall
period for absenteeism (work days missed) is 1 month; recall period for presenteeism (work days with productivity
reduced by 550%, not including work days missed) is 1 month; range for productivity interference is 0–10, where
0 indicates no interference and 10 indicates complete interference. (a) Reduction in absenteeism (work days missed) due
to arthritis. (b) Decrease in presenteeism (days with productivity at paid work reduced by 550%) due to RA. *P40.001 vs
non-responders; **P40.01 vs non-responders. (c) Reduction in the rate of RA interference with productivity at paid work.
*P40.001 vs non-responders; **P40.01 vs non-responders; rate of interference 0–10 scale: 0 indicates no interference
and 10 indicates complete interference.
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Outcomes associated with productivity in RAfunction, fatigue or pain responder status tended to in-
crease when thresholds higher than the MCID were se-
lected to define response (data not shown). An additional
sensitivity analysis was conducted using a responder def-
inition of 20% improvement from baseline in HAQ-DI,
which also showed comparable associations between
productivity and physical function (data not shown).
Discussion
These analyses indicate that RA patients who experienced
clinically meaningful improvements in physical function,
fatigue and pain following treatment with CZP plus MTX
reported significantly greater improvements in work, both
within and outside the home. Findings were consistent,
regardless of which patient-reported outcome was used
to determine a treatment response, which threshold was
used to define MCID and when response was defined
based on 20% improvement in HAQ-DI from baseline (in-
stead of MCID). The use of MCIDs to categorize patients
as responders or non-responders for our primary analysis
was a valid approach as they are clinically relevant for pa-
tients, capturing a level of benefit that can be perceived by
them, and have been well documented in the literature.
Decreased work productivity, as well as decreased par-
ticipation in family, social and leisure activities, reflects the
important impact of RA on patients’ lives. Importantly,
findings presented here indicate that productivity both
within the workplace and at home can be positively influ-
enced by improvements in physical function and relief of
pain and fatigue. In addition, patients treated with CZP in
combination with MTX reported significant relief of
arthritis-associated pain and fatigue as well as improve-
ments in physical function after 3 months of treatment.
Results were particularly striking regarding pain relief,
with five times as many CZP-treated patients reporting
clinically meaningful improvement, and two to three
times as many reporting improvements in physical func-
tion and fatigue compared with patients receiving placebo
plus MTX.
None of the outcome measures was associated with a
statistically significant reduction in absenteeism at paid
work due to RA. Although this could be interpreted to in-
dicate that employed patients with and without clinically
meaningful improvements in physical function or relief
from pain or fatigue have comparable absences from
work, responders in all three categories (i.e. those with
changes 5MCID) reported significant improvements in
productive days at work compared with non-responders
and significantly less interference of RA on productivity
at work. One explanation for this observation may be
that work-leave policies regarding absenteeism (i.e. the
time missed from work due to health reasons) may pre-
vent patients from staying home even when they are
experiencing symptoms [46]. Indeed, our study demon-
strates that although deficits in physical function, pain
and fatigue do not prevent patients from going to work,
they do interfere with their productivity while at work.
Findings also indicate there may be a continuum of dis-
ability that progresses from an initial loss of productivity at
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Johanna M. Hazes et al.work to fewer days worked to ultimately stopping work
altogether. Effective treatment strategies that improve
signs and symptoms of RA would help to stop or reverse
this continuum.
Clinically meaningful improvements in physical function,
fatigue and pain were also associated with statistically
significant improvements in productivity within the home,
including significantly fewer days lost of household work
FIG.2Mean changes in household work productivity and daily activities from baseline to Week 12 by responder status
(observed data, ITT population, pooled RAPID 1 and 2 CZP 200mg+400mg groups). Response is defined as change
from baseline to Week 12 5MCID (in absolute value), non-response is defined as mean change from baseline to Week 12
<MCID. Recall period for household work days missed, household work days with productivity reduced by 550%
(not including household work days missed), leisure days missed and days with hired help is 1 month; range for
productivity interference is 0–10, where 0 indicates no interference and 10 indicates complete interference. (a) Reduction
in days of household work missed due to arthritis. *P40.001 vs non-responders; **P40.01 vs non-responders. (b)
Decrease in days with household productivity reduced by 550% due to RA. *P40.001 vs non-responders. (c) Reduction
in days lost of family, social or leisure activities due to arthritis. *P40.001 vs non-responders; **P40.01 vs
non-responders. (d) Reduction in days with hired outside help. **P40.01 vs non-responders. (e) Reduction in the
rate of RA interference with household work productivity. *P40.001 vs non-responders; rate of interference 0–10 scale:
0 indicates no interference and 10 indicates complete interference.
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Outcomes associated with productivity in RAdue to RA. These findings differ from those reported for
work outside the home, and likely reflect two important
points: (i) only 37–40% of patients enrolled in these trials
were gainfully employed; and (ii) there are differences be-
tween the varying types of work activities (requiring differ-
ing levels of physical performance and energy) performed
outside the home and those done within the home. While
the demands of paid employment at work tend to be
‘fixed’ and highly structured based on work (and societal)
policies, those of housework are more flexible and more
easily delayed or rescheduled and may be more ambigu-
ous based on societal status, family cycle, private nego-
tiations and personal preferences. In addition, unlike paid
employment, household work may be more easily dele-
gated to others, either within the home or done for
payment.
Findings in these analyses are consistent with previous-
ly reported improvements in patient-reported outcomes
following treatment with CZP plus MTX [47] and comple-
ment the significant improvements in disease activity that
have also been observed following CZP plus MTX treat-
ment [27, 28]. Additional analyses have also demonstrated
that the improvements in patient-reported outcomes
(physical function, pain and fatigue) are associated
among each other (Pearson’s coefficients ranging be-
tween 0.54 and 0.77) and that these improvements cor-
relate well with clinical improvements in disease activity
following treatment with CZP plus MTX [47]. Findings in
these analyses are also consistent with those in a study
evaluating the relationship between hiring outside help
and achieving clinical responses to treatment—where
patients with clinically meaningful improvements in pain,
fatigue and physical function reported greater reductions
in the number of days they hired help to perform house-
hold work [48]. In addition to improvement in productivity
inside and outside the home, responders reported signifi-
cantly less interference of RA on the participation in
family, social and leisure activities. This improvement
was significantly associated with reduction in fatigue
and pain, further confirming the inter-related matrix of
the ancillary burdens of disease.
Strengths of this study include the robust findings
from two large well-controlled trials in meeting primary
endpoints of ACR responses as well as radiographic bene-
fit at Weeks 24 and 52, with large effect sizes compared
with placebo plus MTX. In addition, statistically signifi-
cant and meaningful improvements in work and household
productivity as well as participation in family, social and
leisure activities were reported after only 12 weeks of treat-
ment. Future studies are needed to determine whether
these observed improvements are maintained or even
increased with longer exposure to effective treatment.
Limitations include patients being asked to recall events
that occurred in the proceeding month that may introduce
bias in reporting. However, previous research has indi-
cated that individuals are able to accurately report work
days lost over the past 30 days [49].
In summary, results of these analyses from two large
multinational, Phase III clinical trials demonstrate that
CZP significantly improves physical function, fatigue and
pain in patients with active RA, and that there is a clear
association between clinically meaningful improvements
in pain, fatigue and physical function and increased prod-
uctivity within and outside the home, and less interference
of RA with work, household activities and participation in
family, social and leisure activities. These findings have
important societal implications in the context of direct
and indirect costs attributed to active RA.
Rheumatology key messages
. Improved function, pain and fatigue in CZP-treated
RA patients associated with increased work
productivity.
. Increased household productivity associated with
improved function, pain and fatigue in CZP-treated
patients.
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